The interferon treatments in the study included Avonex, Betaseron, and Rebif.
All told, these data don’t mean much from a business standpoint, IMO. The MS market has been gradually moving away from interferon usage, so new data that Copaxone is better than the interferons is unlikely to affect the choice of therapy in a material way.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.